Viusid in Adults With Acute Fever of Viral Etiology

Catalysis SL

Status and phase: Completed; Phase 2

Conditions: Acute Fever of Viral Etiology

Treatments: Drug: Conventional treatment; Dietary Supplement: Viusid

Study type: Interventional

Funder types: Industry

Identifiers

NCT01008007

CAT-0911-CU

Details and patient eligibility

About

The purpose of the study is to assess the safety and effect of Viusid (bags of 4 grams) administration in the treatment of acute fever of viral etiology as diagnosed by clinical, hematologic and serologic parameters. The duration of this open and randomized phase 2 clinical trial will be 6 days. The estimated number of persons with acute fever of viral etiology to be recruited and randomized for the study is 200. The primary outcome measure: platelet, leukocyte and granulocyte count will be assessed at the beginning and the end of the study.

Enrollment: 200 estimated patients

Sex: All

Ages: 18 to 85 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Acute fever of viral etiology with less than 72 hours of progression
• Signed informed consent.

Exclusion criteria

• Patients under treatment with other antioxidants.
• Inability to swallow the content of Viusid bags

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

200 participants in 2 patient groups

A

Experimental group

Description:

Viusid in combination with the conventional treatment for acute fever of viral etiology

Treatment:

Dietary Supplement: Viusid

B

Active Comparator group

Description:

Conventional treatment for acute fever of viral etiology

Treatment:

Drug: Conventional treatment